Ticker Details
Apellis Pharmaceuticals, Inc. Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.
IPO Date:	November 9, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.82B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.98 | 2.79%
Avg Daily Range (30 D):	$0.62 | 2.73%
Avg Daily Range (90 D):	$0.60 | 2.57%

Institutional Daily Volume
Avg Daily Volume:	1.16M
Avg Daily Volume (30 D):	2.38M
Avg Daily Volume (90 D):	2.22M

Trade Size
Avg Trade Size (Sh.):	78
Avg Trade Size (Sh.) (30 D):	78
Avg Trade Size (Sh.) (90 D):	75

Institutional Trades
Total Institutional Trades:	7,973
Avg Institutional Trade:	$3.47M
Avg Institutional Trade (30 D):	$7.37M
Avg Institutional Trade (90 D):	$5.23M
Avg Institutional Trade Volume:	.09M
Avg Institutional Trades (Per Day):	4

Market Closing Trades
Avg Closing Trade:	$7.57M
Avg Closing Trade (30 D):	$16.82M
Avg Closing Trade (90 D):	$11.91M
Avg Closing Volume:	205.79K

News

Feb 23, 2026 @ 12:00 PM Apellis Pharmaceuticals to Present at the TD Cowen... Source: Na

Jan 27, 2026 @ 11:02 PM TTM Technologies, Dutch Bros, Advanced Energy Indu... Source: Prnewswire

Jan 13, 2026 @ 6:04 PM Silver Jumps To $89 After Soft CPI, JPMorgan Falls... Source: Piero Cingari

Jan 12, 2026 @ 12:00 PM Apellis Highlights Commercial Execution and Strate... Source: Apellis Pharmaceuticals, Inc.

Dec 1, 2025 @ 6:00 PM Geographic Atrophy Market to Surge Significantly D... Source: Delveinsight

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$.36	$1.71	$-.33
Diluted EPS	$.36	$1.67	$-.33
Revenue	$1.02B	$458.58M	$178.49M
Gross Profit
Net Income / Loss	$44.99M	$215.72M	$-42.15M
Operating Income / Loss	$80.41M	$223.18M	$-33.29M
Cost of Revenue
Net Cash Flow	$82.36M	$109.14M	$11.64M
PE Ratio	61.11

Splits
Mar 19, 2004	1:200